Post-transcriptional modifications (PTMs) of RNA play crucial roles in the regulation of various biological processes, including anti-tumor immunity. These modifications impact the splicing, translation, degradation, and localization of RNA, and they are essential for proper gene expression. The removal of introns from coding sequences through pre-messenger RNA (mRNA) splicing is one such example of PTMs. Alternative splicing, where varying combinations of exons are linked, also results in different proteins being produced from the original mRNA. RNA editing (e.g., triggered by a cytidine deaminase) is another example of PTMs where changes are induced in the coding information after transcription, resulting in the sequence of RNA differing from the transcribed DNA template. Moreover, RNA methylation (e.g., m6A, m5C, and m7G) is a predominant and significant modification of RNA. Post-transcriptional modifications occur not only in coding RNA but also in noncoding RNAs, such as transfer RNA (tRNA), ribosomal RNA (rRNA), long noncoding RNA (lncRNA), small nuclear RNA (snRNA), and microRNA (miRNA). These modifications have been found to regulate gene expression and contribute to numerous physiological and pathological processes. This Research Topic focuses on the connections between post-transcriptional modifications and cancer immunity and immunotherapy.
The goal of this Research Topic is to provide a forum to advance research on the contribution of post-transcriptional modifications to the molecular mechanisms of anti-tumor immunity as well as to explore innovative PTM-targeted immunotherapies in the attempt to achieve a beneficial impact on cancer patients.
We welcome submissions of Original Research, Systematic Reviews, Mini Reviews, Clinical Trials, Case Reports, and Opinions that focus on, but not limited to, the following sub-topics:
1) Alternative splicing in tumorigenesis and cancer immunity
2) RNA splicing factors/regulators in tumorigenesis and cancer immunity
3) RNA editing in tumor development and immunotherapy
4) Novel RNA modifications in tumor development and immunotherapy
5) New methodologies for studying the PTMs in tumor biology
6) PTM-associated biomarkers for tumor diagnosis and prognosis
7) PTM-targeted strategies for cancer immunotherapy
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Post-transcriptional modifications (PTMs) of RNA play crucial roles in the regulation of various biological processes, including anti-tumor immunity. These modifications impact the splicing, translation, degradation, and localization of RNA, and they are essential for proper gene expression. The removal of introns from coding sequences through pre-messenger RNA (mRNA) splicing is one such example of PTMs. Alternative splicing, where varying combinations of exons are linked, also results in different proteins being produced from the original mRNA. RNA editing (e.g., triggered by a cytidine deaminase) is another example of PTMs where changes are induced in the coding information after transcription, resulting in the sequence of RNA differing from the transcribed DNA template. Moreover, RNA methylation (e.g., m6A, m5C, and m7G) is a predominant and significant modification of RNA. Post-transcriptional modifications occur not only in coding RNA but also in noncoding RNAs, such as transfer RNA (tRNA), ribosomal RNA (rRNA), long noncoding RNA (lncRNA), small nuclear RNA (snRNA), and microRNA (miRNA). These modifications have been found to regulate gene expression and contribute to numerous physiological and pathological processes. This Research Topic focuses on the connections between post-transcriptional modifications and cancer immunity and immunotherapy.
The goal of this Research Topic is to provide a forum to advance research on the contribution of post-transcriptional modifications to the molecular mechanisms of anti-tumor immunity as well as to explore innovative PTM-targeted immunotherapies in the attempt to achieve a beneficial impact on cancer patients.
We welcome submissions of Original Research, Systematic Reviews, Mini Reviews, Clinical Trials, Case Reports, and Opinions that focus on, but not limited to, the following sub-topics:
1) Alternative splicing in tumorigenesis and cancer immunity
2) RNA splicing factors/regulators in tumorigenesis and cancer immunity
3) RNA editing in tumor development and immunotherapy
4) Novel RNA modifications in tumor development and immunotherapy
5) New methodologies for studying the PTMs in tumor biology
6) PTM-associated biomarkers for tumor diagnosis and prognosis
7) PTM-targeted strategies for cancer immunotherapy
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.